Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29362369 | 0.83 | TP53 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL30843524 | 0.83 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL26929285 | 0.83 | TP53 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL52267 | 0.83 | TP53 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL16249319 | 0.79 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL21777465 | 0.79 | CYP3A4 (0.43) | GAA | |
| SCHEMBL13818241 | 0.79 | MAPK1 (0.38) | — | |
| SCHEMBL6899604 | 0.78 | APLNR (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL13818120 | 0.78 | APLNR (0.32) | — | |
| SCHEMBL3632875 | 0.78 | APLNR (0.54) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129094-A1 | NEW QUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-04-24 | — | — | US | claimed |
| EP-4399209-A1 | NEW QUINOLINE DERIVATIVES | Elanco Animal Health GmbH (DE) | 2024-07-17 | — | — | EP | claimed |
| CN-117957223-A | Quinoline derivatives | 礼蓝动物保健有限公司 | 2024-04-30 | — | — | CN | claimed |
| WO-2023036821-A1 | NEW QUINOLINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2023-03-16 | — | — | WO | claimed |
| EP-4148052-A1 | NEW QUINOLINE DERIVATIVES | Bayer Animal Health GmbH (DE) | 2023-03-15 | — | — | EP | claimed |
| WO-2026107328-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4735444-A1 | BENZYL (3-(METHYL(7H-PYRROLO[2,3-D]PYRIMIDIN-4YL)AMINO)CYCLOBUTYL) CARBAMATE OR A SALT THEREOF, METHOD FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE SYNTHESIS OF ABROCITINIB | Moehs Ibérica, S.L. (ES) | 2026-05-06 | — | — | EP | disclosed |
| US-12410179-B2 | Modulators of TNF alpha activity and uses thereof | RAYTHERA, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250263418-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | RAYTHERA, INC. | 2025-08-21 | — | — | US | disclosed |
| EP-4587438-A1 | BICYCLIC COMPOUNDS AS CDK INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-07-23 | — | — | EP | disclosed |
| CN-119894890-A | Bicyclic compounds as CDK inhibitors | 百济神州(苏州)生物科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20250127795-A1 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity | UCB Biopharma SRL (BE) | 2025-04-24 | — | — | US | disclosed |
| EP-1720847-A1 | HISTAMINE-3 RECEPTOR MODULATORS | Pfizer Products Incorporated (US) | 2006-11-15 | — | — | EP | disclosed |
| US-7115600-B2 | Histamine-3 receptor modulators | PFIZER INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1641455-A1 | PYRAZOLO[3,4-B]PYRIDIN-6-ONES AS GSK-3 INHIBITORS | Pfizer Products Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005080361-A1 | HISTAMINE-3 RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| WO-2005000304-A1 | PYRAZOLO[3,4-B]PYRIDIN-6-ONES AS GSK-3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040266815-A1 | Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 inhibitors | PFIZER INC | 2004-12-30 | — | — | US | disclosed |
| WO-2001022919-A2 | SPIRO[BICYCLIC -AZACYCLOALKYL AND -CYCLOALKYL] DERIVATIVES AND USES THEREOF | MERCK & CO., INC. (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410179-B2 | Modulators of TNF alpha activity and uses thereof | TNF, TNFRSF1A, TNFRSF9 | CHRNB2 2308/4885CHRNA4 2062/4885CHRNB4 2199/4885 |
| US-20250129094-A1 | NEW QUINOLINE DERIVATIVES | RECQL, QTRT2, NQO2 | CHRNB2 1191/4885CHRNA4 590/4885CHRNB4 1420/4885 |
| US-20250127795-A1 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | CHRNB2 776/4885CHRNA4 804/4885CHRNB4 1218/4885 |
| US-20250263418-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | TNF, TNFRSF1A, TNFRSF9 | CHRNB2 2308/4885CHRNA4 2062/4885CHRNB4 2199/4885 |
| US-20040266815-A1 | Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | CHRNB2 1136/4885CHRNA4 1552/4885CHRNB4 1323/4885 |
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | HRH3, HRH4, HRH1 | CHRNB2 137/4885CHRNA4 118/4885CHRNB4 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.